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Objectives: Men who have sex with men are at risk of tenofovir nephrotoxicity due to its wide
use  in both treatment and prophylaxis for human immunodeﬁciency virus infection, but
little is known about the urinary biomarkers of early renal dysfunction in this population.
This  study aims to identify useful biomarkers of early renal dysfunction among human
immunodeﬁciency virus-infected men who have sex with men exposed to tenofovir.
Methods: In a cross-sectional study urinary alpha1-microglobulin, beta2-microglobulin,
N-acetyl--d-glucosaminidase and albumin were measured and expressed as the ratio-to-
creatinine in 239 human immunodeﬁciency virus-infected men who have sex with men
who were treatment naïve or receiving antiretroviral therapy with tenofovir-containing
or  non-tenofovir-containing regimens. Additionally, 56 patients in the non-antiretroviraltherapy group started a tenofovir-containing regimen and were assessed after 3 and 6
iral therapy.months on antiretrovResults: Both the frequency of alpha1-microglobulin proteinuria (alpha1-microglobulin-
creatinine ratio >25.8 mg/g) and the median urinary alpha1-microglobulin-creatinine ratio
were higher in the tenofovir disoproxil fumarate group than the other two groups
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(all p < 0.05). A higher frequency of beta2-microglobulin proteinuria (beta2-microglobulin-
creatinine ratio >0.68 mg/g) was also observed in the tenofovir group (28.9%) compared to
the non-tenofovir group (13.6%, p = 0.024). There were no signiﬁcant differences between
groups for N-acetyl--d-glucosaminidase and albumin. In the longitudinal study, the
median urinary alpha1-microglobulin-creatinine ratio after 3 and 6 months on tenofovir-
containing therapy (16.8 and 17.3 mg/g) was higher than baseline (12.3 mg/g, p = 0.023 and
0.011, respectively), while no statistically important changes were observed in urinary
beta2-microglobulin-creatinine ratio or in the other biomarkers after 3 and 6 months on
antiretroviral therapy (all p > 0.05).
Conclusion: Urinary alpha1-microglobulin seems to be a more sensitive and stable indica-
tor  of tubular dysfunction than urinary beta2-microglobulin for assessing tenofovir-related
nephrotoxicity and can be signiﬁcantly altered after tenofovir exposure.
©  2015 Elsevier Editora Ltda. All rights reserved.
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he prevalence of HIV-associated kidney disease has
ecreased in the era of antiretroviral therapy (ART), but
rug-induced nephrotoxicity is emerging.1 Long-term expo-
ure to nephrotoxic antiretroviral drugs, such as tenofovir
isoproxil fumarate (TDF), may lead to progression of renal
ysfunction and incomplete reversibility of toxicity, even
fter drug withdrawal.2,3 Moreover, some urinary biomarkers
f early kidney injury were found to be associated with
mportant clinical outcomes, such as mortality and severe
eart disease.4,5 Therefore, it is important to detect early
enal dysfunction in HIV-infected individuals, particularly in
hose exposed to TDF.
TDF is widely used as a preferential drug for ART according
o worldwide guidelines, and it is also part of the only approved
egimen for pre-exposure prophylaxis to HIV infection.6 The
rug is excreted through glomerular ﬁltration and proximal
ubular secretion, and its use has been related to an increased
isk of rapid decline in renal function and chronic kidney
isease.2 Clinically, renal insufﬁciency is usually assessed by
n estimated glomerular ﬁltration rate (eGFR),7 but proxi-
al  tubular dysfunction is more  common and speciﬁc for
DF-induced toxicity8 and can occur with the absence of
lomerular defects.9
The evaluation of urinary biomarkers, such as 1-
icroglobulin (1M), 2-microglobulin (2M)  and N-acetyl-
-d-glucosaminidase (NAG), may improve the identiﬁcation
f those at risk of tubular toxicity and may detect early
tages of renal dysfunction.10,11 However, the evaluation crite-
ia of these proteins in tubular dysfunction have not been
stablished and little is known about the change of these
ew biomarkers during ART. The role of the aforementioned
iomarkers in diagnosing and monitoring early tubular dam-
ge still needs to be explored.
HIV transmission is increasing markedly faster among
SM  than other high-risk groups in China and some other
ountries.12,13 MSM  are at risk of TDF toxicity due to its com-
rehensive role in treatment and pre-exposure prophylaxis.
owever, most biomarkers of early renal dysfunction have not
een validated in HIV-infected patients let alone in speciﬁc
ey-populations, such as MSM.  Our study aims to investigatethe presence of early renal dysfunction among HIV-infected
MSM and to ﬁnd the indicators of early renal injury in MSM
with TDF exposure.
Materials  and  methods
Study  population
We  performed a cross-sectional study and a longitudinal study
with a single-center cohort of HIV-infected MSM  at the First
Hospital of China Medical University in Shenyang, a major
city in northern China that has a rapidly increasing incidence
of HIV infection among MSM.14 A total of 239 MSM  receiving
care at the AIDS clinic were enrolled in a cross-sectional study
between August 2012 and June 2014. All participants in the
study were adults (age ≥18 years) who were treatment-naïve
or had received the current ART regimen for no less than six
months. The patients who had used other non-ART nephro-
toxic drugs in the previous two months before enrollment
were excluded from the study.
The ART regimens were based on either Efavirenz (EFV)
or Lopinavir/ritonavir (LPV/r). The other two  ART drugs were
lamivudine (3TC) plus TDF (TDF group) and 3TC plus zidovu-
dine (AZT) (non-TDF group). Fifty-six patients in the non-ART
group who started TDF/3TC/EFV were enrolled in a longitudi-
nal study and were assessed after 3 and 6 months on ART. This
study was approved by the Medical Research Ethics Commit-
tee of the First Hospital of China Medical University. Written
informed consent for participation in this study was obtained
from each participant.
Data  collection
Demographic characteristics; medical history, such as dia-
betes, hypertension, and prior AIDS-deﬁning illness; and other
clinical and laboratory data of each subject were obtained
from the clinical records and laboratory database. Body weight
was also measured. Fasting blood and mid-stream urine spec-
imens were collected at the routine morning consultation.
Blood samples were assayed for full blood count, CD4T cell
count, HIV RNA level, 2M,  and routine biochemistry levels,
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Fig. 1 – Proportion of tubular and glomerular proteinuria
among the study groups.
Albuminuria was deﬁned as ACR >30 mg/g. Other kinds of
proteinuria were  deﬁned as 2MCR >0.68 mg/g, 1MCR
>25.8 mg/g, and NAGCR >9.1 IU/g, respectively. ACR, urinary
albumin-to-creatinine ratio; 2MCR,
beta2-microglobulin-to-creatinine ratio; 1MCR,
alpha1-microglobulin-to-creatinine ratio; NAGCR,
N-acetyl--d-glucosaminidase-to-creatinine ratio.412  b r a z j i n f e c t d 
including renal, liver, glucose, calcium, phosphorus, and lipid
proﬁles.
Spot urine samples were tested for 1M, 2M,  NAG,
creatinine, and albumin within four hours after sample col-
lection in the clinical laboratory of our hospital. The urinary
levels of 1M,  2M and albumin were determined by a
Siemens BN II nephelometer Analyzer II with the kits from
Siemens. NAG was measured with a 6-methyl-2-pyridinethiol
(MPT) assay (Leadman Biotechnologies Inc., Beijing), and uri-
nary creatinine was measured by enzymatic methods using
an automated multianalyzer (HITACHI 7600, Tokyo, Japan).
The upper reference limits given by the manufacturer were
0.3 mg/L for urinary 2M,  12 mg/L for urinary 1M,  and
11.5 IU/L for NAG. All of the urinary proteins were expressed
as the ratio-to-creatinine (1MCR, 2MCR, NAGCR, and ACR)
to account for the variations in urine concentration among
individuals.
Deﬁnition
Hypertension was self-reported or diagnosed as a systolic BP
≥140, diastolic BP ≥90 mmHg, or current treatment of hyper-
tension with antihypertensive drugs. Diabetes was deﬁned as
a fasting blood glucose ≥7.0 mmol/L or a self-reported his-
tory of diabetes. Hypocalcemia and hypophosphatemia were
deﬁned based on the reference ranges in the local clinical labo-
ratory as serum calcemia <2.17 mmol/L and serum phosphate
<0.81 mmol/L. The eGFR was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKDEPI).15 Albu-
minuria was deﬁned as an ACR >30 mg/g.16 Because there are
no accepted criteria for the proteinuria of 1M,  2M and NAG,
we used the upper quartile (UQ) values of 1MCR, 2MCR and
NAGCR of all participants to deﬁne abnormality.
Statistical  analysis
All analyses were performed using SPSS software, ver-
sion 18.0 (SPSS, Inc., Chicago, IL, USA). Data are presented
as means ± standard deviation (mean ± SD), medians with
inter-quartile ranges (IQR) for continuous variables, and as
proportions for categorical variables. Appropriate variables
were compared by one-way ANOVA and independent-sample
t tests for continuous variables; 2 test or Fisher exact test
for categorical variables. We calculated Spearman rank cor-
relation coefﬁcients to determine the relationship between
urinary proteins and serum 2M.  Risk factors of UQ 2MCR and
UQ 1MCR were identiﬁed with multivariate logistic regres-
sion analysis. We  considered a p-value <0.05 to be statistically
signiﬁcant.
Results
Two-hundred-thirty-nine HIV-infected MSM  were enrolled in
the study and stratiﬁed by ART into the three groups: TDF
group (n = 97), non-TDF group (n = 66), and non-ART group
(n = 76). The characteristics of the participants are given in
Table 1. In the study sample, the frequency of hypertension,
diabetes and hypophosphatemia were 2.9% (n = 7), 2.5% (n = 6),
and 9.6% (n = 23), respectively. Although almost half of thepatients in the TDF group were treatment experienced with a
non-TDF-containing regimen, the total ART time in both ART
groups was similar (p > 0.05).
In the cross-sectional study, an eGFR < 90 mL/min/1.73 m2
was seen in eight patients (3.3%) and an eGFR < 60 mL/min/
1.73 m2 was seen in only two patients (0.8%). Albuminuria
was present in 12.1% of our participants. As shown in Fig. 1
and Table 2, the TDF group had a higher frequency of 1M
proteinuria (1MCR >25.8 mg/g) and a higher 1MCR value
than the other two groups (all p < 0.05). A higher frequency
of 2M proteinuria (2MCR >0.68 mg/g) was also observed in
the TDF group compared to the non-TDF group (p = 0.024). No
signiﬁcant differences were found in 2MCR among the three
groups. Statistical analysis revealed no signiﬁcant differences
in abnormal frequency or ratio-to-creatinine value of urinary
NAG and albumin among the three groups.
2MCR and 1MCR (in urine) were both correlated with
serum 2M (Fig. 2A and B, all p < 0.001). In multivariate
analyses, TDF exposure (OR 2.62, 95%CI 1.09, 6.30), body
weight <60 kg (OR 3.05, 95%CI 1.45, 6.40), and an eGFR
<90 mL/min/1.73 m2 (OR 13.77, 95%CI 2.37, 80.03) were asso-
ciated with UQ 1MCR; after adjusting for serum 2M,  TDF
exposure (OR 4.16, 95%CI 1.43, 12.10), body weight <60 kg (OR
3.30, 95%CI 1.43, 7.63), and the cumulative time on ART (OR
1.02, 95%CI 1.00, 1.04) were related to UQ 1MCR (Table 3).
Moreover, protease inhibitor exposure (OR 3.09, 95%CI 1.00,
9.55), CD4 cell count <200 cells/mm3 (OR 2.96, 95%CI 1.40,
6.25), and eGFR <90 mL/min/1.73 m2 (OR 25.26, 95%CI 2.74,
232.71) were associated with UQ 2MCR; after adjusting for
serum 2M, only cumulative time on ART (OR 1.02, 95%CI
1.00, 1.04) was related to UQ 2MCR (Table 4). Factors with
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Table 1 – Demographic and clinical characteristics of the HIV-infected MSM.
TDF (n = 97) Non-TDF (n = 66) Non-ART (n = 76) All (n = 239) p-Value
Body weight (kg) Mean ± SD 65.6 ± 9.2 66.7 ± 9.6 67.5 ± 10.7 66.5 ± 9.8 0.459
Age (years) Mean ± SD 38.7 ± 10.0 39.1 ± 12.5 35.4 ± 12.5 37.7 ± 11.6 0.102
Hepatitis B surface Ag (positive) N (%) 10 (10.3) 1 (1.5) 6 (7.9) 17 (7.1) 0.100
Hepatitis C Antibody (positive) N (%) 3 (3.1) 0 (0) 3 (3.9) 6 (2.5) 0.283
Current eGFR (mL/min/1.73 m2) Mean ± SD 118.0 ± 11.4 119.4 ± 14.6 116.3 ± 16.5 117.8 ± 14.1 0.409
Baseline eGFR(CKDEPI)(mL/min/1.73 m2) Mean ± SD 112.3 ± 18.8 109.3 ± 19.7 0.369
Current CD4 cell count (cells/mm3) Mean ± SD 349.4 ± 186.2 301.3 ± 124.9 203.5 ± 152.2 291.6 ± 171.6 <0.001a
Nadir CD4 cell count (cells/mm3) Mean ± SD 165.2 ± 124.2 203.1 ± 75.7 178.7 ± 113.4 0.203
Current HIV RNA (log10) Mean ± SD 0.86 ± 1.36 0.66 ± 1.20 4.79 ± 0.75 2.03 ± 2.18 <0.001a
Serum 2M (mg/L) Mean ± SD 2.42 ± 0.56 2.13 ± 0.81 3.67 ± 1.39 2.71 ± 1.13 <0.001a
Prior AIDS-deﬁning illness N  (%) 22 (22.7) 10 (15.2) 20 (26.3) 52 (21.8) 0.178
Hypocalcemia N (%) 14 (14.4) 10 (15.2) 21 (27.6) 45 (18.8) 0.215
Hypophosphatemia N (%) 13 (13.4) 5 (7.6) 5 (6.6) 23 (9.6) 0.355
Diabetes N (%) 1 (1.0) 4 (6.0) 1 (1.3) 6 (2.5) 0.097
Hypertension N (%) 2 (2.1) 3 (4.5) 2 (2.6) 7 (2.9) 0.705
On LPV/r N (%) 25 (25.8) 1 (1.5) <0.001a
On initial regimen N (%) 44 (45.3) 61 (92.4) <0.001a
Time on current regimen (months) Mean ± SD 12.9 ± 10.9 21.7 ± 15.9 <0.001a
Time on ART (months) Mean ± SD 24.1 ± 24.7 21.7 ± 15.9 0.479
p-Value for comparison between the three groups.
TDF, tenofovir disoproxil fumarate; ART, antiretroviral therapy; eGFR, estimated glomerular ﬁltration rate; 2M, beta2-microglobulin; AIDS,
acquired immune deﬁciency syndrome; LPV/r, lopinavir/ritonavir.
a A signiﬁcant difference between the groups compared.
Table 2 – The levels of urinary proteins in the subjects.
TDF (n = 97) Non-TDF (n = 66) Non-ART (n = 76) All (n = 239) p-Value
Urinary 2MCR (mg/g) Median (IQR) 0.26 (0.14, 0.77) 0.14 (0.09, 0.29) 0.30 (0.15, 0.91) 0.23 (0.13, 0.68) 0.325
Urinary 1MCR (mg/g) Median (IQR) 17.2 (10.9, 30.0) 12.7 (9.1, 21.6) 14.1 (8.4, 21.0) 15.4 (9.2, 25.8) 0.028a
Urinary NagCR (IU/g) Median (IQR) 5.6 (4.1, 8.5) 6.2 (4.1, 9.2) 6.1 (3.90, 10.5) 6.0 (4.0, 9.1) 0.411
Urinary ACR (mg/g) Median (IQR) 8.7 (4.7, 16.1) 6.6 (4.0, 13.6) 7.3 (4.7, 11.4) 7.4 (4.4, 13.9) 0.586
p-Value for comparison between the three groups.
2MCR, beta2-microglobulin-creatinine ratio; 1MCR, alpha1-microglobulin-creatinine ratio; NAGCR, N-acetyl--D-glucosaminidase-creatinine
t
(
w
T
uratio; ACR, albumin-creatinine ratio (urine).
a A signiﬁcant difference between the groups compared.
oo low prevalence, such as diabetes (2.5%) and hypertension
2.9%), were not included in the analysis.
To further study the impact of TDF on kidney function,
e followed-up 56 MSM  from the non-ART group who started
DF/3TC/EFV. As shown in Table 5, 1MCR was the only
rinary biomarker that dramatically increased after three and
Table 3 – Factors associated with upper quartile (UQ) 1MCR in 
2M).
OR (95%CI) 
Body weight <60 kg 3.05 (1.45, 6.40) 
Age >50 years 1.29 (0.49, 3.39) 
eGFR <90 mL/min/1.73 m2 13.77 (2.37, 80.03) 
CD4 cell count <200 cells/mm3 1.70 (0.80, 3.61) 
TDF exposure 2.62 (1.09, 6.30) 
LPV/r exposure 0.88 (0.29, 2.70) 
Cumulative TDF (increase by year) 1.03 (0.97, 1.08) 
Cumulative ART (increase by year) 1.01 (0.99, 1.02) 
eGFR, estimated glomerular ﬁltration rate; TDF, tenofovir disoproxil fumarsix months on TDF-containing therapy compared to baseline
data (p = 0.023 and 0.011, respectively). There was a slight
increasing trend of 2MCR (in the urine) at three months,
but it disappeared at six months (all p > 0.05), concurrent
with a signiﬁcant decrease in 2M after six months of ART
(p = 0.028).
multivariate analysis (unadjusted or adjusted by serum
p-Value Adjusted OR (95%CI) p-Value
0.003 3.30 (1.43, 7.63) 0.005
0.605 0.54 (0.17, 1.71) 0.292
0.030 1.50 (0.15, 15.27) 0.732
0.165 0.72 (0.29, 1.77) 0.469
0.032 4.16 (1.43, 12.10) 0.009
0.820 0.45 (0.13, 1.56) 0.207
0.355 1.05 (0.98, 1.11) 0.189
0.452 1.02 (1.00, 1.04) 0.047
ate; LPV/r, lopinavir/ritonavir; ART, antiretroviral therapy.
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Table 4 – Factors associated with upper quartile (UQ) 2MCR in multivariate analysis (unadjusted or adjusted by serum
2M).
OR (95%CI) p-Value Adjusted OR (95%CI) p-Value
Body weight <60 kg 1.65 (0.76, 3.61) 0.208 1.49 (0.65, 3.40) 0.349
Age >50 years 1.29 (0.49, 3.40) 0.607 0.66 (0.22, 1.98) 0.459
eGFR <90 mL/min/1.73 m2 25.26 (2.74, 232.71) 0.004 5.75 (0.42, 78.07) 0.188
CD4 cell count <200 cells/mm3 2.96 (1.40, 6.25) 0.004 1.79 (0.77, 4.14) 0.178
TDF exposure 1.31 (0.52, 3.29) 0.569 1.03 (0.96, 1.09) 0.447
LPV/r exposure 3.09 (1.00, 9.55) 0.050 2.00 (0.63, 6.37) 0.240
Cumulative TDF (increase by year) 1.01 (0.96, 1.07) 0.694 1.03 (0.96, 1.09) 0.447
Cumulative ART (increase by year) 1.007 (0.99, 1.03) 0.488 1.02 (1.00, 1.04) 0.052
eGFR, estimated glomerular ﬁltration rate; TDF, tenofovir disoproxil fumarate; LPV/r, lopinavir/ritonavir; ART, antiretroviral therapy.
Table 5 – Longitudinal observation of urinary biomarkers in patients exposed to TDF-containing regimen.
Baseline 3 months p-Value 6 months p′-Value
eGFR (mL/min/1.73 m2) Mean ± SD 116.4 ± 16.7 121.2 ± 11.7 0.105 118.4 ± 14.3 0.523
Urinary ACR (mg/g) Median (IQR) 6.5 (4.2, 10.6) 8.6 (5.9, 12.8) 0.989 8.7 (5.3, 14.5) 0.171
Serum 2M (mg/L) Mean ± SD 3.43 ± 1.49 2.80 ± 1.36 0.052 2.80 ± 1.19 0.028a
Urinary 2MCR (mg/g) Median (IQR) 0.29 (0.15, 0.62) 0.33 (0.19, 1.11) 0.371 0.29 (0.16, 0.65) 0.467
Urinary 1MCR (mg/g) Median (IQR) 12.3 (7.2, 19.0) 16.8 (9.4, 26.0) 0.023a 17.3 (8.9, 29.5) 0.011a
Urinary NagCR (IU/g) Median (IQR) 5.9 (3.8, 10.5) 4.9 (4.0, 8.9) 0.60 5.7 (3.8, 9.0) 0.466
p-Value for comparison between baseline and 3 months of ART, and p′-val
a A signiﬁcant difference between the groups compared.
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Discussion
In an era in which early ART and pre-exposure prophylaxis
are generally encouraged,17 TDF use and its nephrotoxicity are
likely to draw increasing attention.18 In HIV-infected females,
some urinary biomarkers were related to TDF use and could
forecast declining kidney function.19,20 Among HIV-infected
MSM, we  observed a higher rate of 1M and 2M proteinuria
in TDF users in a cross-sectional study and conﬁrmed uri-
nary 1M elevation after TDF exposure in a longitudinal study.
HIV-seronegative MSM  were found to have a small but signif-
icant decrease in creatinine clearance after TDF exposure,21
but novel urinary biomarkers among this population have not
been evaluated. Our ﬁndings underscored the importance of
subclinical renal function monitoring in HIV-infected MSM
treated with TDF, and the ﬁndings might also give clues
for early detection of TDF-related toxicity in non-infected
MSM.
Here we chose four urinary candidate markers to indicate
early renal dysfunction: albuminuria is a classical indicator
of early glomerular injury;22 1M, 2M, and NAG are tubular
biomarkers, but their role in diagnosing and monitoring
early tubular damage is still undetermined. Of all of the
selected markers, urinary 1M seems to be the most reliable
for determining TDF-associated renal dysfunction in several
ways. First, urinary 1M was the only biomarker that could
distinguish the TDF group from the other two  control groups
in the cross-sectional study. Second, 1M was also the only
marker with notable elevation after ART initiation assessed
in the longitudinal study. In a review paper, TDF-related renal
damage usually appears within 5–12 months after initiation
of therapy.23 Our observation conﬁrmed the sensitivity of
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rinary 1M,  which increased signiﬁcantly already after three
onths of TDF-containing therapy. Third, we  observed no
igniﬁcant differences in albumin or NAG in cross-sectional
r longitudinal studies. Urinary 2M might also be a help-
ul biomarker, which has been recommended along with
rinary 1M as a useful screening tool for TDF-induced
idney tubulopathy in a diagnostic accuracy study,10 and
howed a higher rate of proteinuria in the TDF group than
he non-TDF group in our study. However, urinary 2M is
ighly dependent on serum 2M and the pH value of the
rine.24,25 Unlike 2M, which is unstable in acidic urine, 1M
as been reported to be very stable in urine at different
Hs.26
It is worth mentioning that the inﬂammatory status
f HIV infection may disturb the interpretation of urinary
iomarkers in tubular dysfunction because 1M and 2M
re both inﬂammatory biomarkers.26,27 In our observation,
rinary 1MCR and 2MCR were both correlated to serum
2M,  which is a non-speciﬁc marker of chronic inﬂamma-
ion and could be increased even after ART.27,28 However,
erum 2M seemed to have a stronger effect on urinary
2MCR than urinary 1MCR. In multivariate analyses, TDF
xposure was an independent risk factor for UQ 1MCR
efore and after serum 2M adjustment. By contrast, after
djusting for serum 2M,  all traditional risk factors of tubu-
ar proteinuria29 lost their signiﬁcance in association with
Q 2MCR. In the longitudinal study, we  also observed ele-
ated 1MCR levels after three and six months on TDF
xposure, but no obvious change was found in 2MCR after
RT, probably due to the decreased level of serum 2M.
evertheless, in another study with a longer observation
ime after TDF than in our study, urinary 2M was highly
levated.19 It reminds us that urinary 2M may still be a useful
arker after long-term TDF exposure and encourages further
tudy.
Our study provided information about the presence of early
enal dysfunction in Chinese HIV-infected patients. Com-
ared with another HIV-infected cohort of African Americans
nd Caucasians in America, our patients had a lower rate
f albuminuria (12.1% versus 28%). A recent study in Ger-
any reported a higher rate of albuminuria (20%), but a lower
ate of tubular proteinuria (41%) than that seen in our study
54.4%), as measured by their deﬁnition (1MCR >14 mg/g).30
ore  studies using similar biomarkers and criteria of early
enal dysfunction are needed. Additionally, because TDF only
ecame a ﬁrst-line drug to treat naive patients in China in
012, future studies are required to determine its long-term
oxicity in Chinese patients.
onclusion
rinary 1M seems to be a promising biomarker for early
etection of TDF-associated tubular dysfunction among HIV-
nfected MSM.  Urinary 2M may help indicate tubular
ysfunction, but its clinical interpretation should also take
nﬂammatory conditions into account. More studies will be
ecessary to address the clinical role of these biomark-
rs in diagnosing and monitoring TDF-associated tubular
njury.
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